Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Overview of Cell-Matrix Interactions

Overview of Cell-Matrix Interactions

The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...

Cancer-Critical Genes I: Proto-oncogenes

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Protocol to screen for Sorafenib resistance regulators using pooled lentiviral shRNA library and a Sorafenib-resistant hepatocellular carcinoma cell model.

STAR protocols·2023

Same author

Tracking and characterization of partial and full epithelial-mesenchymal transition cells in a mouse model of metastatic breast cancer.

STAR protocols·2022

Same author

Distinct contributions of partial and full EMT to breast cancer malignancy.

Developmental cell·2021

Same author

Hierarchy of TGFβ/SMAD, Hippo/YAP/TAZ, and Wnt/β-catenin signaling in melanoma phenotype switching.

Life science alliance·2021

Same author

YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis.

EMBO molecular medicine·2021

Same author

Author Correction: Guidelines and definitions for research on epithelial-mesenchymal transition.

Nature reviews. Molecular cell biology·2021

Same journal

Role of oral microbiome in cancer immunotherapy.

Seminars in cancer biology·2026

Same journal

Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

Seminars in cancer biology·2026

Same journal

Hidden architecture of resistance: The extracellular matrix in melanoma's immune landscape.

Seminars in cancer biology·2026

Same journal

Microfluidic technologies for extracellular vesicle isolation and analysis: Implications for translational applications in cancer therapy.

Seminars in cancer biology·2026

Same journal

Exploring glioblastoma microenvironment using organoids: opportunities, limitations, and emerging concepts.

Seminars in cancer biology·2026

Same journal

Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease.

Seminars in cancer biology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

The angiogenic switch in carcinogenesis.

Vanessa Baeriswyl¹, Gerhard Christofori

¹Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Mattenstrasse 28, CH-4058 Basel, Switzerland.

Seminars in Cancer Biology

|June 2, 2009

Summary

This summary is machine-generated.

The "angiogenic switch" triggers tumor growth by shifting the balance of growth factors. Transgenic mouse models help study this switch and develop better anti-angiogenic therapies.

More Related Videos

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

Published on: February 16, 2018

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Experiment Videos

Last Updated: Jun 22, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

Published on: February 16, 2018

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Area of Science:

Oncology
Molecular Biology
Cancer Research

Background:

The "angiogenic switch" describes a critical transition in tumor progression.
This switch involves a shift in the balance of pro- and anti-angiogenic factors.
It facilitates the change from dormant to vascularized, malignant tumors.

Purpose of the Study:

Investigate the molecular mechanisms of the angiogenic switch.
Identify key pro- and anti-angiogenic factors involved.
Explore the role of inflammation in tumor angiogenesis.

Main Methods:

Characterization of molecular players in the angiogenic switch.
Utilizing transgenic mouse models of cancer.
Assessing novel anti-angiogenic therapies and resistance mechanisms.

Main Results:

Numerous pro-angiogenic factors and angiogenic inhibitors have been identified.
Transgenic mouse models recapitulate tumor progression and angiogenesis.
Inflammatory responses are critical for tumor angiogenesis onset.

Conclusions:

Understanding the angiogenic switch is crucial for cancer therapy.
Transgenic models provide insights into angiogenesis and therapy resistance.
Research contributes to improving anti-angiogenic therapies for clinical use.